In clinical trials, the expansion and persistence of CAR-T cells correlate with therapeutic efficacy. However, properties of CAR-T cells that enable their in vivo proliferation have still to be consistently defined and the role of CAR-T bag content has never been investigated in a real life setting.
Phenotypic composition of commercial anti-CD19 CAR-T cells affects in vivo expansion and disease response in large B-cell lymphoma patients / C. Monfrini, F. Stella, V. Aragona, M. Magni, S. Ljevar, C. Vella, E. Fardella, A. Chiappella, F. Nanetti, M. Pennisi, A. Dodero, A. Guidetti, P. Corradini, C. Carniti. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - 28:15(2022 May 18), pp. 3378-3386. [10.1158/1078-0432.CCR-22-0164]
Phenotypic composition of commercial anti-CD19 CAR-T cells affects in vivo expansion and disease response in large B-cell lymphoma patients
F. StellaSecondo
;M. Magni;E. Fardella;M. Pennisi;A. Guidetti;P. Corradini
;
2022
Abstract
In clinical trials, the expansion and persistence of CAR-T cells correlate with therapeutic efficacy. However, properties of CAR-T cells that enable their in vivo proliferation have still to be consistently defined and the role of CAR-T bag content has never been investigated in a real life setting.File | Dimensione | Formato | |
---|---|---|---|
3378.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
874.98 kB
Formato
Adobe PDF
|
874.98 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.